Similar articles

• [Clinical problems of the natural coagulation and fibrinolysis inhibitors--introduction (author's transl)].

  Aoki N. Aoki N. Rinsho Ketsueki. 1978 Jul;19(7):917-9. Rinsho Ketsueki. 1978. PMID: 81326 Japanese. No abstract available.
• [Blood coagulation and fibrinolysis inhibitory factors].

  Imaoka S, Sasaki Y, Terasawa T. Imaoka S, et al. Rinsho Byori. 1985 Jun;Spec No 63:55-61. Rinsho Byori. 1985. PMID: 2413229 Review. Japanese. No abstract available.
• Plasma coagulation proteases, proteolytic inhibitors, and their interaction with platelets.

  Rao AK, Schmaier AH, Colman RW. Rao AK, et al. Pathobiol Annu. 1982;12:35-64. Pathobiol Annu. 1982. PMID: 6186978 Review. No abstract available.
• [Relationship between antiplasmin capacity and concentration of alpha 2-plasmin inhibitor, alpha 2-macroglobulin, alpha 1-antitrypsin, antithrombin III or C1-inactivator in plasma of patients with transient ischemic attacks (author's transl)].

  Matsuda T, Seki T, Miura R, Ogawara M, Yokouchi M, Yamanouchi H. Matsuda T, et al. Rinsho Byori. 1980 Mar;28(3):261-4. Rinsho Byori. 1980. PMID: 6154815 Japanese. No abstract available.
• ACL automated method for plasma inhibitors.

  Creter D. Creter D. Haematologica. 1990 Nov-Dec;75(6):582. Haematologica. 1990. PMID: 1711504 No abstract available.